Importantly, in this case report, two R/R AML patients with initial IDH1-R132C mutation achieved durable remissions with therapy of ivosidenib, but leukemia cells recurred with emergence of neomorphic mutation IDH2-R140Q. This evidence concerns the gene IDH1 and acute myeloid leukemia.